http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#Head http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#assertion http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#provenance http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#pubinfo http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#assertion http://purl.obolibrary.org/obo/DOID_1920 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1920 http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB04854 http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association http://www.w3.org/2000/01/rdf-schema#label uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable for the safe and effective use of allopurinol see allopurinol prescribing information uloric is a xanthine oxidase xo inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol who are intolerant to allopurinol or for whom treatment with allopurinol is not advisable 1 for the safe and effective use of allopurinol see allopurinol prescribing information limitations of use uloric is not recommended for the treatment of asymptomatic hyperuricemia 1 limitations of use uloric is not recommended for the treatment of asymptomatic hyperuricemia http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB04854 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#provenance http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#pubinfo http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig http://purl.org/nanopub/x/hasSignature gyF42SyJ4DWGVjSoJtjuz/OVtAHQe+2LpGJXBfIKceslvqwMAqVJwonY7XO9IIpnOH2dH/CoT46QNc9Q+i2PdpHBQS231SSHpT3qnIYpvhe3GpW7721ANs5DLpnWGvbUygw57sK3G1kCZOMwQEHvytYcI7kSXKVnwoPczkHK/LE= http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://purl.org/dc/terms/created 2021-06-12T13:28:40.734+02:00 http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAF-4-wPzMnx34c1JaQa2-4se-g64RhGavWTAM5goflNU https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs